Solid Biosciences Inc.

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia

Solid Biosciences received European Commission Orphan designation for SGT-212, its gene therapy for Friedreich's ataxia, granting incentives including reduced fees and 10 years of EU market exclusivity if approved. The company also said five participants have been dosed in the Phase 1b FALCON trial with no treatment-related serious adverse events as of October 5, 2026. Initial FALCON clinical data is expected in Q1 2027, which will be the first meaningful read on the dual-route delivery approach.

•6d ago

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

Solid Biosciences will present seven accepted abstracts at the ESGCT Annual Congress in Hamburg, October 27-30, 2026. The posters cover SGT-003, the company's Duchenne muscular dystrophy gene therapy now in Phase 1/2 and Phase 3 trials, as well as the POLARIS-101 capsid platform and rAAV manufacturing advances. The announcement is a visibility event rather than new data; investors should watch the poster content for any incremental SGT-003 signals.

•12d ago

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences reported a strengthened cash position of $377.7 million, extending its runway into mid-2028, supported by $60.8 million in ATM proceeds during the first half of 2026. The company initiated dosing in the Phase 3 IMPACT DUCHENNE trial for SGT-003 and plans to meet with the FDA in late Q4 2026 to discuss an accelerated approval pathway. The SGT-212 program for Friedreich’s ataxia continues with two participants dosed in the Phase 1b FALCON trial, with initial data expected in Q1 2027.

•2mo ago

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

Solid Biosciences has dosed the first participant in its Phase 3 IMPACT DUCHENNE trial evaluating SGT-003 for Duchenne muscular dystrophy, a randomized, placebo-controlled study designed to support potential accelerated approval. The Phase 1/2 INSPIRE DUCHENNE trial has now dosed 46 participants with SGT-003, which has been generally well tolerated with no observed cases of serious adverse events like drug-induced liver injury or myocarditis. The company received a positive opinion from the EMA on its Pediatric Investigation Plan and holds multiple FDA designations for SGT-003, including Fast Track, Rare Pediatric, and Orphan Drug status.

•5mo ago

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Solid Biosciences received Orphan Drug Designation from the European Commission for SGT-003, its investigational gene therapy for Duchenne muscular dystrophy. The designation grants 10 years of market exclusivity in the EU upon approval and complements existing Fast Track and Rare Pediatric Disease designations in the U.S. SGT-003 is currently being evaluated in the ongoing Phase 1/2 INSPIRE DUCHENNE trial and the Phase 3 IMPACT DUCHENNE trial.

•6mo ago